Kadar C-Reactive Protein (CRP) sebagai Prediktor Terjadinya Kematian pada Pasien Kanker dengan Komplikasi Infeksi
Main Article Content
Abstract
Tujuan: Penelitian ini bertujuan mengetahui peran kadar C-reactive protein (CRP) dalam memprediksi terjadinya kematian pada pasien kanker dengan komplikasi infeksi. Metode: Penelitian ini merupakan studi prospektif pada pasien kanker solid dan hematologi berusia diatas 18 tahun yang menjalani perawatan di rumah sakit. Kurva Kapplan Meier digunakan untuk memperoleh median dan overall survival. Analisis cox regression digunakan untuk memperoleh hazard rasio (HR) kadar CRP dalam memprediksi terjadinya kematian. Hasil: Kami mendapatkan perbedaan kurva survival pada pasien dengan CRP yang tinggi dibandingkan dengan kadar CRP yang rendah. Hazard rasio untuk kadar CRP adalah 11,07 (IK 95% 3,13 – 39,10), p<0,001. Pada analisis multivariat, kadar CRP memiliki adjusted HR 2.00 (IK 95% 1.33 – 11.98), p=0.048). Simpulan: Pasien kanker dengan komplikasi infeksi dengan kadar CRP tinggi memiliki angka kematian yang lebih tinggi dibandingkan dengan pasien dengan kadar CRP yang rendah. Implikasi: kadar CRP dapat digunakan sebagai prediktor terjadinya kematian pada pasien kanker dengan komplikasi infeksi.
Article Details
How to Cite
SUASTIKA, Ngakan Ketut Wira; SUEGA, Ketut.
Kadar C-Reactive Protein (CRP) sebagai Prediktor Terjadinya Kematian pada Pasien Kanker dengan Komplikasi Infeksi.
Prosiding Seminar Nasional Sains dan Teknologi (Senastek), [S.l.], v. 9, n. 1, p. 7-13, dec. 2024.
Available at: <https://ojs.unud.ac.id/index.php/senastek/article/view/118514>. Date accessed: 04 feb. 2025.
Section
Articles
References
[1] M. K. Elfaituri et al., ‘Incidence of Infection-related mortality in cancer patients: Trend and survival analysis.’, Journal of Clinical Oncology, vol. 37, no. 15\_suppl, pp. e23095–e23095, 2019, doi: 10.1200/JCO.2019.37.15\_suppl.e23095.
[2] B. Islas-Muñoz, P. Volkow-Fernández, C. Ibanes-Gutiérrez, A. Villamar-Ramírez, D. Vilar-Compte, and P. Cornejo-Juárez, ‘Bloodstream infections in cancer patients. Risk factors associated with mortality’, International Journal of Infectious Diseases, vol. 71, 2018, doi: 10.1016/j.ijid.2018.03.022.
[3] J. D. Faix, ‘Biomarkers of sepsis’, 2013. doi: 10.3109/10408363.2013.764490.
[4] G. Leuzzi et al., ‘Baseline C-reactive protein level predicts survival of early-stage lung cancer: Evidence from a systematic review and meta-analysis’, 2016. doi: 10.5301/tj.5000522.
[5] S. Hong, Y. A. Kang, B. C. Cho, and D. J. Kim, ‘Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer’, Yonsei Med J, vol. 53, no. 1, 2012, doi: 10.3349/ymj.2012.53.1.111.
[6] D. Wiese, K. Kampe, J. Waldmann, A. E. Heverhagen, D. K. Bartsch, and V. Fendrich, ‘C-reactive protein as a new prognostic factor for survival in patients with pancreatic neuroendocrine Neoplasia’, Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 3, 2016, doi: 10.1210/jc.2015-3114.
[7] S. Mitsunaga et al., ‘C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer’, Pancreas, vol. 45, no. 1, 2016, doi: 10.1097/MPA.0000000000000465.
[8] R. V. Cooney, W. Chai, A. A. Franke, L. R. Wilkens, L. N. Kolonel, and L. Le Marchand, ‘C-reactive protein, lipid-soluble micronutrients, and survival in colorectal cancer patients’, Cancer Epidemiology Biomarkers and Prevention, vol. 22, no. 7, 2013, doi: 10.1158/1055-9965.EPI-13-0199.
[9] B. Å. Andersson et al., ‘Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma’, J Cancer Res Clin Oncol, vol. 140, no. 3, 2014, doi: 10.1007/s00432-014-1592-8.
[10] X. Song et al., ‘Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis’, 2021. doi: 10.1155/2021/3456629.
[11] D. S. Kim et al., ‘Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma’, Korean Journal of Internal Medicine, vol. 32, no. 4, 2017, doi: 10.3904/kjim.2016.054.
[12] H. J. A. Adams et al., ‘Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma’, Clin Lymphoma Myeloma Leuk, vol. 15, no. 11, 2015, doi: 10.1016/j.clml.2015.07.639.
[13] J. Wang, M. Zhou, X. Wang, J. Xu, B. Chen, and J. Ouyang, ‘Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP’, Clinica Chimica Acta, vol. 459, 2016, doi: 10.1016/j.cca.2016.05.033.
[14] R. Haase et al., ‘Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical hodgkins lymphoma (HL)’, Klin Padiatr, vol. 224, no. 6, 2012, doi: 10.1055/s-0032-1323824.
[15] J. Zuo et al., ‘C-reactive protein levels, the prognostic nutritional index, and the lactate dehydrogenase-to-lymphocyte ratio are important prognostic factors in primary central nervous system lymphoma: a single-center study of 223 patients’, Neurosurg Rev, vol. 47, no. 1, 2024, doi: 10.1007/s10143-023-02248-1.
[16] P. Liang and F. Yu, ‘Value of CRP, PCT, and NLR in Prediction of Severity and Prognosis of Patients With Bloodstream Infections and Sepsis’, Front Surg, vol. 9, 2022, doi: 10.3389/fsurg.2022.857218.
[17] H. Sano et al., ‘Risk factors for sepsis-related death in children and adolescents with hematologic and malignant diseases’, Journal of Microbiology, Immunology and Infection, vol. 50, no. 2, 2017, doi: 10.1016/j.jmii.2015.04.002.
[18] O. Karasahin, P. T. Tasar, O. Timur, F. Yıldırım, D. N. Binici, and S. Sahin, ‘The value of C-reactive protein in infection diagnosis and prognosis in elderly patients’, Aging Clin Exp Res, vol. 30, no. 6, 2018, doi: 10.1007/s40520-017-0821-9.
[19] Ö. Devran et al., ‘C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit’, Multidiscip Respir Med, vol. 7, no. 6, 2012, doi: 10.1186/2049-6958-7-47.
[20] C. S. D. Roxburgh and D. C. McMillan, ‘Role of systemic inflammatory response in predicting survival in patients with primary operable cancer’, 2010. doi: 10.2217/fon.09.136.
[21] W. Ansar and S. Ghosh, ‘Biology of C reactive protein in health and disease’, Biology of C Reactive Protein in Health and Disease, pp. 1–301, 2016, doi: 10.1007/978-81-322-2680-2.
[22] H. Sano et al., ‘Risk factors for sepsis-related death in children and adolescents with hematologic and malignant diseases’, Journal of Microbiology, Immunology and Infection, vol. 50, no. 2, 2017, doi: 10.1016/j.jmii.2015.04.002.
[2] B. Islas-Muñoz, P. Volkow-Fernández, C. Ibanes-Gutiérrez, A. Villamar-Ramírez, D. Vilar-Compte, and P. Cornejo-Juárez, ‘Bloodstream infections in cancer patients. Risk factors associated with mortality’, International Journal of Infectious Diseases, vol. 71, 2018, doi: 10.1016/j.ijid.2018.03.022.
[3] J. D. Faix, ‘Biomarkers of sepsis’, 2013. doi: 10.3109/10408363.2013.764490.
[4] G. Leuzzi et al., ‘Baseline C-reactive protein level predicts survival of early-stage lung cancer: Evidence from a systematic review and meta-analysis’, 2016. doi: 10.5301/tj.5000522.
[5] S. Hong, Y. A. Kang, B. C. Cho, and D. J. Kim, ‘Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer’, Yonsei Med J, vol. 53, no. 1, 2012, doi: 10.3349/ymj.2012.53.1.111.
[6] D. Wiese, K. Kampe, J. Waldmann, A. E. Heverhagen, D. K. Bartsch, and V. Fendrich, ‘C-reactive protein as a new prognostic factor for survival in patients with pancreatic neuroendocrine Neoplasia’, Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 3, 2016, doi: 10.1210/jc.2015-3114.
[7] S. Mitsunaga et al., ‘C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer’, Pancreas, vol. 45, no. 1, 2016, doi: 10.1097/MPA.0000000000000465.
[8] R. V. Cooney, W. Chai, A. A. Franke, L. R. Wilkens, L. N. Kolonel, and L. Le Marchand, ‘C-reactive protein, lipid-soluble micronutrients, and survival in colorectal cancer patients’, Cancer Epidemiology Biomarkers and Prevention, vol. 22, no. 7, 2013, doi: 10.1158/1055-9965.EPI-13-0199.
[9] B. Å. Andersson et al., ‘Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma’, J Cancer Res Clin Oncol, vol. 140, no. 3, 2014, doi: 10.1007/s00432-014-1592-8.
[10] X. Song et al., ‘Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis’, 2021. doi: 10.1155/2021/3456629.
[11] D. S. Kim et al., ‘Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma’, Korean Journal of Internal Medicine, vol. 32, no. 4, 2017, doi: 10.3904/kjim.2016.054.
[12] H. J. A. Adams et al., ‘Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma’, Clin Lymphoma Myeloma Leuk, vol. 15, no. 11, 2015, doi: 10.1016/j.clml.2015.07.639.
[13] J. Wang, M. Zhou, X. Wang, J. Xu, B. Chen, and J. Ouyang, ‘Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP’, Clinica Chimica Acta, vol. 459, 2016, doi: 10.1016/j.cca.2016.05.033.
[14] R. Haase et al., ‘Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical hodgkins lymphoma (HL)’, Klin Padiatr, vol. 224, no. 6, 2012, doi: 10.1055/s-0032-1323824.
[15] J. Zuo et al., ‘C-reactive protein levels, the prognostic nutritional index, and the lactate dehydrogenase-to-lymphocyte ratio are important prognostic factors in primary central nervous system lymphoma: a single-center study of 223 patients’, Neurosurg Rev, vol. 47, no. 1, 2024, doi: 10.1007/s10143-023-02248-1.
[16] P. Liang and F. Yu, ‘Value of CRP, PCT, and NLR in Prediction of Severity and Prognosis of Patients With Bloodstream Infections and Sepsis’, Front Surg, vol. 9, 2022, doi: 10.3389/fsurg.2022.857218.
[17] H. Sano et al., ‘Risk factors for sepsis-related death in children and adolescents with hematologic and malignant diseases’, Journal of Microbiology, Immunology and Infection, vol. 50, no. 2, 2017, doi: 10.1016/j.jmii.2015.04.002.
[18] O. Karasahin, P. T. Tasar, O. Timur, F. Yıldırım, D. N. Binici, and S. Sahin, ‘The value of C-reactive protein in infection diagnosis and prognosis in elderly patients’, Aging Clin Exp Res, vol. 30, no. 6, 2018, doi: 10.1007/s40520-017-0821-9.
[19] Ö. Devran et al., ‘C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit’, Multidiscip Respir Med, vol. 7, no. 6, 2012, doi: 10.1186/2049-6958-7-47.
[20] C. S. D. Roxburgh and D. C. McMillan, ‘Role of systemic inflammatory response in predicting survival in patients with primary operable cancer’, 2010. doi: 10.2217/fon.09.136.
[21] W. Ansar and S. Ghosh, ‘Biology of C reactive protein in health and disease’, Biology of C Reactive Protein in Health and Disease, pp. 1–301, 2016, doi: 10.1007/978-81-322-2680-2.
[22] H. Sano et al., ‘Risk factors for sepsis-related death in children and adolescents with hematologic and malignant diseases’, Journal of Microbiology, Immunology and Infection, vol. 50, no. 2, 2017, doi: 10.1016/j.jmii.2015.04.002.